A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The role of systemic chemotherapy in advanced biliary tract cancer (BTC) is known to be very
limited although various single-agent or combination therapies had been tested. However,
there is a possibility that palliative chemotherapy induce prolong survival and improve
quality of life in advanced BTC based on several studies. A GERCOR study showed the promising
result of gemcitabine in combination with oxaliplatin as first line chemotherapy in advanced
BTC. Therefore, this phase II trial was planned to investigate efficacy and toxicity of
combination chemotherapy with gemcitabine and dose adjusted oxaliplatin in patients with
inoperable BTC in Korea.